FIBROLAMELLAR CARCINOMA
Clinical trials for FIBROLAMELLAR CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new FIBROLAMELLAR CARCINOMA trials appear
Sign up with your email to follow new studies for FIBROLAMELLAR CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New cocktail of four drugs aims to tackle childhood cancers that Won't go away
Disease control Recruiting nowThis study is testing a combination of four drugs—atezolizumab, sorafenib, bevacizumab, and cyclophosphamide—in children and young adults with solid tumors that have come back or not responded to standard treatment. The goal is to find safe doses and see if the combination can sh…
Matched conditions: FIBROLAMELLAR CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New hope for rare cancers: immunotherapy drug targets tumors regardless of origin
Disease control Recruiting nowThis study tests the drug nivolumab in people with advanced rare cancers that have a specific marker (PD-L1). The goal is to see if the drug can shrink or control the tumors when other treatments have stopped working. Up to 28 adults will receive treatment for up to 12 months, an…
Matched conditions: FIBROLAMELLAR CARCINOMA
Phase: PHASE2 • Sponsor: Instituto do Cancer do Estado de São Paulo • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Keytruda takes on childhood liver cancer: new hope for relapsed patients?
Disease control Recruiting nowThis phase 2 trial is testing the immunotherapy drug pembrolizumab (Keytruda) in children and young adults up to age 30 with relapsed or hard-to-treat liver cancer. The goal is to see if the drug can shrink tumors or slow the cancer's growth. Researchers will also study how the i…
Matched conditions: FIBROLAMELLAR CARCINOMA
Phase: PHASE2 • Sponsor: Allison O'Neill, MD • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC